NCT-05996445

A Phase 1, First-in-Human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of XmAb®662 in Monotherapy or in Combination with Pembrolizumab in Advanced Solid Tumors

This medical study is designed to study XmAb 662, a new drug that is being developed to treat advanced solid tumors. The drug will be given to patients in two ways: either as a single agent (monotherapy) or in combination with pembrolizumab. Pembrolizumab is a type of immunotherapy drug called a PD-1 inhibitor. It works by blocking a protein called PD-1, which helps cancer cells evade the immune system. By blocking PD-1, pembrolizumab can help the immune system attack and kill cancer cells.

Advanced: Advanced cancer means that the cancer cells from the original tumor (primary tumor) get loose, spread by traveling through the body, and start a new tumor (metastatic tumor) somewhere else in the body.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05996445

NCT05996445

Clinical Trial Site: Sinai

To see all available clinical trials click here.